Celon Pharma (FRA:8RP) Inventories, Work In Process: €0.83 Mil (As of Mar. 2026)


FRA:8RP Celon Pharma SA FRA:8RP
48 GF Score
Price €4.39
GF Value €5.11
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Inventories, Work In Process?

Celon Pharma FRA:8RP +0.11% 48 Inventories, Work In Process is €0.83 Mil as of Mar. 2026. GuruFocus rates FRA:8RP with a GF Score™ of 48/100 and a GF Value™ of €5.11. The stock has 3 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Celon Pharma's work in process for the quarter that ended in Mar. 2026 was €0.83 Mil.

Celon Pharma Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Celon Pharma's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma Inventories, Work In Process Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 2.24 3.60 0.00 0.00

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 1.53 0.96 0.00 0.83
FRA:8RP
48GF Score
Celon Pharma SA FRA:8RP
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €0.83 Mil mean?
Celon Pharma (FRA:8RP) has a Inventories, Work In Process of €0.83 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's Inventories, Work In Process too high?
Celon Pharma's current Inventories, Work In Process is €0.83 Mil. Overall, Celon Pharma has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's Inventories, Work In Process compare to ZTS and UTHR?
Celon Pharma's Inventories, Work In Process of €0.83 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Celon Pharma and its competitors. Celon Pharma's current Inventories, Work In Process is €0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (FRA:8RP) has a current Inventories, Work In Process of €0.83 Mil. The stock's GF Value™ is €5.11, compared to a current price of €4.39 — trading 14.1% below its estimated fair value. The current Inventories, Work In Process is €0.83 Mil. Celon Pharma's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Celon Pharma (FRA:8RP), the current Inventories, Work In Process is €0.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (FRA:8RP) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of €4.39 is trading 14.1% below its estimated GF Value™ of €5.11.

Key valuation signals for FRA:8RP:

  • Inventories, Work In Process: €0.83 Mil
  • GF Value™: €5.11 vs. price of €4.39 (14.1% below fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
48GF Score

Get the complete analysis for FRA:8RP

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.39
Price
€5.11
GF Value